BidaskClub upgraded shares of Intellia Therapeutics (NASDAQ:NTLA) from a hold rating to a buy rating in a research note released on Friday morning.

NTLA has been the subject of a number of other research reports. Oppenheimer reaffirmed a hold rating on shares of Intellia Therapeutics in a research report on Monday, December 18th. Credit Suisse Group increased their price objective on shares of Intellia Therapeutics from $24.00 to $28.00 and gave the stock an outperform rating in a research report on Friday, November 3rd. TheStreet cut shares of Intellia Therapeutics from a c- rating to a d rating in a research report on Thursday, December 14th. ValuEngine cut shares of Intellia Therapeutics from a hold rating to a sell rating in a research report on Wednesday, November 15th. Finally, Barclays reaffirmed a buy rating on shares of Intellia Therapeutics in a research report on Sunday, November 5th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company. The stock currently has an average rating of Hold and a consensus price target of $30.17.

Shares of Intellia Therapeutics (NTLA) opened at $24.48 on Friday. Intellia Therapeutics has a one year low of $10.83 and a one year high of $33.34. The firm has a market cap of $988.95 and a P/E ratio of -15.79.

In other Intellia Therapeutics news, major shareholder Institutes For Biomed Novartis sold 1,523,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $18.30, for a total value of $27,870,900.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Caribou Biosciences, Inc. sold 550,645 shares of the firm’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $26.78, for a total transaction of $14,746,273.10. The disclosure for this sale can be found here. Insiders have sold a total of 2,521,928 shares of company stock valued at $51,883,434 in the last ninety days. 12.80% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently modified their holdings of the business. BlackRock Inc. boosted its position in Intellia Therapeutics by 1.9% in the 4th quarter. BlackRock Inc. now owns 1,710,947 shares of the company’s stock valued at $32,885,000 after buying an additional 31,662 shares during the period. ARK Investment Management LLC boosted its position in Intellia Therapeutics by 269.2% in the 4th quarter. ARK Investment Management LLC now owns 1,375,149 shares of the company’s stock valued at $26,430,000 after buying an additional 1,002,671 shares during the period. Vanguard Group Inc. boosted its position in Intellia Therapeutics by 10.2% in the 2nd quarter. Vanguard Group Inc. now owns 997,288 shares of the company’s stock valued at $15,957,000 after buying an additional 92,580 shares during the period. GMT Capital Corp purchased a new position in Intellia Therapeutics in the 3rd quarter valued at approximately $8,214,000. Finally, Granahan Investment Management Inc. MA boosted its position in Intellia Therapeutics by 7.0% in the 3rd quarter. Granahan Investment Management Inc. MA now owns 286,144 shares of the company’s stock valued at $7,111,000 after buying an additional 18,784 shares during the period. 48.11% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Intellia Therapeutics (NTLA) Upgraded to “Buy” by BidaskClub” was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://theolympiareport.com/2018/02/13/intellia-therapeutics-ntla-upgraded-to-buy-by-bidaskclub.html.

About Intellia Therapeutics

Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.